Clinical trials: Sexual Dysfunction
Menopause, Vulvovaginal Atrophy
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and…
- Conditions
- Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
- Trial name
- NCT02449902
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- TherapeuticsMD
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Sexual Dysfunction, Physiological
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
This randomized, double-blind, placebo-controlled clinical trial investigated the effect of once daily oral administration of 20 mg estetrol monohydrate tablet for 12 weeks in postmenopausal women who experienced sexual arousal…
- Trial name
- NCT06308614
- Testing
- Estetrol
- Where
- 24 sites in United States
- Volunteers
- 82 people
- Sponsor
- Estetra
Sexual Dysfunction, Physiological
The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy
The purpose of the study is to measure the efficacy of flexible dosing of dapoxetine in a setting similar to routine clinical practice.
- Trial name
- NCT01063881
- Testing
- Dapoxetine
- Where
- 13 sites in Australia, South Korea and 1 more
- Volunteers
- 285 people
- Sponsor
- Janssen Research & Development, LLC
Premature Ejaculation
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.
- Trial name
- NCT02232425
- Testing
- IX-01
- Where
- 10 sites in United States, Australia
- Volunteers
- 88 people
- Sponsor
- Ixchelsis Limited
Erectile Dysfunction
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
- Trial name
- NCT00895011
- Testing
- Avanafil
- Where
- 51 sites in United States
- Volunteers
- 298 people
- Sponsor
- VIVUS LLC
Erectile Dysfunction
Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis)
The purpose of this study is to evaluate modifications to the AMS 700 Series pump, cylinders, reservoir and rear tip extender design, their impact on ease of use for the patient, and ease of implantation for the physician.
- Trial name
- NCT00636506
- Testing
- AMS 700 IPP with MS Pump
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- American Medical Systems
Ejaculation Delayed
A Clinical Investigation to Assess the Effectiveness of Benzocaine in NRL Condoms in Healthy Adult Men Who Feel They Ejaculate Too Quickly During Vaginal Sex
The investigation is to evaluate the effectiveness of benzocaine in two NRL condoms compared with a standard NRL control without benzocaine in prolonging time to ejaculation in healthy adult men who feel they ejaculate too…
- Trial name
- NRL (NCT05840172)
- Testing
- Test condom A (NRL condom with 5% benzocaine paste), Test condom B (NRL condom with 3% benzocaine paste), Control NRL condom
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Erectile Dysfunction
Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction
This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile…
- Trial name
- NCT00631969
- Testing
- Vardenafil ODT (STAXYN, BAY38-9456)
- Where
- 47 sites in Belgium, France and 4 more
- Volunteers
- 362 people
- Sponsor
- Bayer
Erectile Dysfunction
Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
This study is being conducted to compare the safety and efficacy of 2 doses of avanafil to placebo in diabetic men with mild to severe erectile dysfunction.
- Trial name
- REVIVE-D (NCT00809471)
- Testing
- avanafil
- Where
- 39 sites in United States
- Volunteers
- 390 people
- Sponsor
- VIVUS LLC
Sexual Dysfunction, Physiological
Efficacy of VR101 as a Personal Lubricant
This Clinical Investigation (CI03) is designed to validate the efficacy of the VR101 lubricating Intravaginal Ring (IVR) as a personal lubricant device.
- Trial name
- NCT04288752
- Testing
- VR101 Lubricating Intravaginal Ring
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- J3 Bioscience, Inc.
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Impotence
Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life
To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man…
- Trial name
- NCT00422734
- Testing
- tadalafil
- Where
- 19 sites in United States, Austria and 3 more
- Volunteers
- 342 people
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks.
- Trial name
- NCT04984993
- Testing
- MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female)
- Where
- 18 sites in United States, Bulgaria and 2 more
- Volunteers
- 116 people
- Sponsor
- Futura Medical Developments Ltd.
Erectile Dysfunction, Cardiovascular Diseases
Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years.
- Conditions
- Erectile Dysfunction, Cardiovascular Diseases, Male Urogenital Diseases
- Trial name
- NCT01150903
- Testing
- no intervention
- Volunteers
- 98,832 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as…
- Trial name
- NCT00734604
- Testing
- tadalafil once a day [T(OaD)], sildenafil citrate as needed [S(PRN)], tadalafil as needed [T(PRN)]
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Dyspareunia, Vaginal Dryness
Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action
This clinical investigation will look at the effectiveness and safety of two personal lubricants for the relief of intimate discomfort associated with vaginal dryness.
- Trial name
- NCT05644444
- Testing
- Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant), Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)
- Where
- Germany
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Premature Ejaculation
A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation
To determine if an on demand dosing of 50 mg or 150 mg of GSK557296 demonstrates superior efficacy with respect to duration of intra vaginal ejaculatory latency time (IELT) during an 8 week study period compared to placebo in men…
- Trial name
- NCT01021553
- Testing
- GSK557296
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction
The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED).
- Trial name
- NCT02224846
- Testing
- Tadalafil
- Where
- 17 sites in China
- Volunteers
- 635 people
- Sponsor
- Eli Lilly and Company
Fragile X Syndrome, FXS
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome.
- Conditions
- Fragile X Syndrome, FXS, Fra(X) Syndrome
- Trial name
- NCT03569631
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tetra Discovery Partners